Hypertension management: rationale for triple therapy based on mechanisms of action.
about
Single-Pill Combination of Perindopril/Indapamide/Amlodipine in Patients with Uncontrolled Hypertension: A Randomized Controlled Trial.Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects.Safety and effectiveness of a fixed-dose combination of olmesartan, amlodipine, and hydrochlorothiazide in clinical practice.Molecular targets of antihypertensive peptides: understanding the mechanisms of action based on the pathophysiology of hypertensionIdentification of known drugs targeting the endoplasmic reticulum stress response.Optimizing combination therapy in the management of hypertension: the role of the aliskiren, amlodipine, and hydrochlorothiazide fixed combination.Add-on effect of hydrochlorothiazide 12.5 mg in Japanese subjects with essential hypertension uncontrolled with losartan 50 mg and amlodipine 5 mg.Perindopril/amlodipine (Prestalia(®)): a review in hypertension.The potential of food protein-derived anti-inflammatory peptides against various chronic inflammatory diseases.Triple Combination Therapy for Global Cardiovascular Risk: Atorvastatin, Perindopril, and Amlodipine.Triple-combination therapy in the treatment of hypertension: a review of the evidence.Synergism of amlodipine and candesartan on blood pressure reduction and organ protection in hypertensive rats.Blood pressure reduction and control with fixed-dose combination perindopril/amlodipine: A Pan-Hellenic prospective observational study.Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension
P2860
Q33734032-174BE9A1-8D3F-498B-9EBB-467B4B3CFBEDQ34505760-3EFFD7F5-6CB6-478F-B2EF-26D21449C281Q34764232-2C489DC6-16A1-423B-9ED3-496205274403Q35016422-5DD23C0B-697C-49E8-9EB6-EDB3B8E1C4E7Q35618325-494F7F00-DB58-4758-AC50-A571B6962A8DQ36975796-4020D20A-7119-4071-BE7A-FFF62A707A54Q38415677-92CBE3BB-6BE1-4AA0-88F4-A1EE2C834319Q38581126-34DD9E37-40AE-42B9-A168-6BF696D44429Q38681495-0B3E335F-2F3D-4BCA-8076-1ECFA7A64A42Q38852188-067C1FFB-438B-47E2-A2C0-BF6764FDC6CEQ39147724-95497699-B3D1-407E-B973-C76A415510C8Q49380661-5351A3D9-15A9-4C9D-BA2C-F27E0316245AQ50993176-A6781B8C-D7AE-4EFE-A56A-B912541C715FQ58362678-1A695870-8CF5-4B49-89EA-D0E1171F322E
P2860
Hypertension management: rationale for triple therapy based on mechanisms of action.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Hypertension management: rationale for triple therapy based on mechanisms of action.
@en
type
label
Hypertension management: rationale for triple therapy based on mechanisms of action.
@en
prefLabel
Hypertension management: rationale for triple therapy based on mechanisms of action.
@en
P2860
P356
P1476
Hypertension management: rationale for triple therapy based on mechanisms of action.
@en
P2093
David H G Smith
Joel M Neutel
P2860
P304
P356
10.1111/1755-5922.12015
P577
2013-10-01T00:00:00Z